Prismasol 4 mmol/l Potassium solution for haemodialysis/haemofiltration
- Name:
Prismasol 4 mmol/l Potassium solution for haemodialysis/haemofiltration
- Company:
Baxter Healthcare Ltd
- Active Ingredients:
Calcium Chloride Dihydrate, Glucose Monohydrate, Lactic Acid, Magnesium chloride, hexahydrate, Potassium Chloride, Sodium Chloride, Sodium Hydrogen Carbonate
- Legal Category:
Product subject to medical prescription which may not be renewed (A)
Summary of Product Characteristics last updated on medicines.ie: 9/8/2018
Click on this link to Download PDF directly
Baxter Healthcare Ltd

Company Products
Medicine Name | Active Ingredients |
---|---|
Medicine Name Hemosol B0 solution for haemodialysis/haemofiltration | Active Ingredients Calcium Chloride, Lactic Acid, Magnesium chloride, Sodium Chloride, Sodium Hydrogen Carbonate |
Medicine Name PHOXILIUM 1.2 mmol/l phosphate Solution for haemodialysis/ haemofiltration | Active Ingredients Calcium Chloride, Disodium phosphate, Magnesium chloride, Potassium Chloride, Sodium Chloride, Sodium Hydrogen Carbonate |
Medicine Name Prismasol 4 mmol/l Potassium solution for haemodialysis/haemofiltration | Active Ingredients Calcium Chloride Dihydrate, Glucose Monohydrate, Lactic Acid, Magnesium chloride, hexahydrate, Potassium Chloride, Sodium Chloride, Sodium Hydrogen Carbonate |
Items Per Page :
1 - 0 of 3 items.Total: Infinity pages
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 9 August 2018 SmPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 1 September 2016 SmPC
Reasons for updating
- New SmPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)